Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DM69TL
|
|||
| Drug Name |
Z-Phe-Ala-diazomethylketone
|
|||
| Synonyms |
Z-Phe-Ala-Diazomethylketone; 71732-53-1; CHEMBL2179950; carbobenzoxycarbonyl-phenylalanyl-alaninyldiazomethane; ZPAD; Z-FA-DMK; SCHEMBL9364460; SCHEMBL17747846; SCHEMBL17747847; ZINC4899534; BDBM50400264; MFCD00077029; (Z,3S)-1-diazonio-3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]but-1-en-2-olate; Q27278127; benzyl (S)-1-((S)-4-diazo-3-oxobutan-2-ylamino)-1-oxo-3-phenylpropan-2-ylcarbamate; benzyl N-[(2S)-1-[[(2S)-4-diazo-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Preclinical | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H22N4O4
|
|||
| Canonical SMILES |
CC(C(=O)C=[N+]=[N-])NC(=O)C(CC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2
|
|||
| InChI |
1S/C21H22N4O4/c1-15(19(26)13-23-22)24-20(27)18(12-16-8-4-2-5-9-16)25-21(28)29-14-17-10-6-3-7-11-17/h2-11,13,15,18H,12,14H2,1H3,(H,24,27)(H,25,28)/t15-,18-/m0/s1
|
|||
| InChIKey |
QMPATRQNERZOMF-YJBOKZPZSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin B (CTSB) | Target Info | Inhibitor | [1] |
| Cathepsin L (CTSL) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Lysosome | |||
| Phagosome | ||||
| Antigen processing and presentation | ||||
| Proteoglycans in cancer | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| TCR Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| Reactome | Endosomal/Vacuolar pathway | |||
| Collagen degradation | ||||
| Degradation of the extracellular matrix | ||||
| Trafficking and processing of endosomal TLR | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| MHC class II antigen presentation | ||||
| WikiPathways | Primary Focal Segmental Glomerulosclerosis FSGS | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.